The Alzheimer's disease therapeutics market is undergoing a significant transformation, valued at approximately USD 4 billion in 2025 across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan. According to DelveInsight, this market is projected to expand at a compound annual growth rate (CAGR) of 22.7% through 2036. This growth trajectory is fueled by increasing disease prevalence, broader adoption of disease-modifying therapies, advancements in biomarker-based diagnosis, and a robust late-stage pipeline targeting complementary pathological pathways beyond conventional amyloid-focused strategies.

The shift toward earlier diagnosis and biologically targeted treatment approaches has strengthened the regulatory landscape. LEQEMBI (lecanemab) has emerged as a leading biologic for early-stage Alzheimer's disease, demonstrating the ability to slow cognitive and functional deterioration in biomarker-confirmed individuals. The anticipated approval of LEQEMBI IQLIK, a subcutaneous maintenance formulation, aims to enhance patient convenience by enabling at-home administration. Similarly, KISUNLA (donanemab) offers clinically meaningful reductions in disease progression with the potential to discontinue treatment after achieving amyloid plaque clearance.

While disease-modifying biologics reshape therapeutic strategies, symptomatic treatments remain integral to clinical management. ZUNVEYL (benzgalantamine), a next-generation oral acetylcholinesterase inhibitor, is designed to improve gastrointestinal tolerability and long-term adherence. ALLODONE transdermal donepezil patches provide an alternative delivery option for elderly patients. Additionally, REXULTI (brexpiprazole) addresses agitation associated with Alzheimer's disease dementia, reflecting a growing emphasis on managing neuropsychiatric symptoms alongside cognitive impairment.

Suven Life Sciences 's Masupirdine (SUVN-502) stands out among six emerging late-stage therapies highlighted for their potential to enter the market. As a highly selective serotonin 5-HT6 receptor antagonist, Masupirdine is developed to treat cognitive impairment and neuropsychiatric manifestations, particularly agitation, in patients with Alzheimer's disease. Unlike conventional treatments that may cause sedation, Masupirdine aims to offer a non-sedating option by selectively modulating central serotonergic pathways. The therapy is currently being assessed in a global Phase III clinical trial evaluating its efficacy in treating agitation associated with Alzheimer's disease dementia. The study is expected to conclude by the end of 2026, with topline results anticipated during the first half of 2027. In June 2026, Suven Life Sciences announced encouraging results from a pre-specified interim analysis and an independent review by the Data and Safety Monitoring Board (DSMB), supporting the continuation of the development program.

Other key candidates in the pipeline include Roche's Trontinemab, an investigational bispecific monoclonal antibody using Brainshuttle technology to enhance anti-amyloid delivery across the blood–brain barrier, with regulatory filings expected after 2028. Axsome Therapeutics' AXS-05, an NMDA receptor antagonist, has received Breakthrough Therapy Designation for agitation associated with Alzheimer's disease. Bristol Myers Squibb's COBENFY (KarXT), a muscarinic M1/M4 receptor agonist, is advancing through Phase III studies for Alzheimer's disease psychosis, with topline results expected in 2026 and potential market entry as early as 2027. Eli Lilly's Remternetug targets N3pG amyloid-beta species and is undergoing Phase III evaluation. Annovis Bio's Buntanetap, a first-in-class Translational Inhibitor of Neurotoxic Aggregating Proteins (TINAPs), is being assessed in Phase III trials for early Alzheimer's disease.

Pipeline Overview

What the Numbers Show

The projected CAGR of 22.7% indicates a rapid acceleration in market valuation, driven not just by volume but by the introduction of high-value disease-modifying therapies. The diversification of mechanisms—from amyloid clearance to serotonergic modulation and muscarinic receptor targeting—suggests that future market share will depend on differentiated efficacy profiles and safety tolerability, particularly regarding sedation and adverse effects. The concentration of late-stage assets addressing agitation and psychosis highlights a significant unmet need in managing behavioral symptoms, positioning companies like Suven Life Sciences and Bristol Myers Squibb to capture substantial value if their Phase III outcomes meet expectations.

suven life sciences filed its Business Responsibility and Sustainability Report (BRSR) for FY26 with the Bombay Stock Exchange and the National Stock Exchange on July 30, 2026. The filing, mandated under Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, reveals that exports constitute 70% of the company’s total turnover, serving markets in four international countries alongside domestic operations in two Indian states. This high export dependency underscores the company’s integration into global pharmaceutical supply chains, where regulatory compliance and safety standards are critical for sustaining revenue streams.

The report covers standalone operations and was assured by J. Sundharesan & Associates, which provided limited assurance on the working of the company’s policies. Suven Life Sciences operates three plants and one office nationally, with no international facilities. The company’s primary business activity is scientific research and development, accounting for 100% of its turnover. CSR provisions under Section 135 of the Companies Act, 2013 are not applicable as the company does not meet the specified thresholds.

Workforce and Human Capital

As of the end of FY26, the company employed 142 permanent employees, comprising 102 males and 40 females, along with 39 non-permanent workers. The Board of Directors includes two women, representing 33.33% of the total board strength. Key Management Personnel (KMP) includes one female member, accounting for 50% of the KMP group.

The permanent employee turnover rate for FY26 stood at 9.28%, a significant decline from 19% in FY25 and 24% in FY24. This reduction suggests improved retention strategies or stabilization in workforce dynamics. The company reported no differently abled employees or workers. All permanent employees and non-permanent workers received health insurance coverage. Additionally, 100% of permanent employees underwent performance and career development reviews.

Environmental and Safety Metrics

The company reported total energy consumption of 6,635.70 Gigajoules in FY26, an increase from 5,606.06 Gigajoules in FY25. All energy consumed was from non-renewable sources. Greenhouse gas emissions totaled 1,340.76 metric tonnes of CO2 equivalent, combining Scope 1 emissions of 45.00 metric tonnes and Scope 2 emissions of 1,295.76 metric tonnes. This represents an increase from the previous year’s total of 915.60 metric tonnes.

Water withdrawal amounted to 2,007.50 kilolitres, primarily from third-party sources, with consumption at 1,807.5 kilolitres. Waste generation increased slightly to 11.347 metric tonnes, consisting mainly of bio-medical waste (11.172 metric tonnes) and battery waste (0.175 metric tonnes). All waste was disposed of via incineration. No safety-related incidents, fatalities, or lost-time injuries were reported during the year.

Governance and Risk Management

The Board of Directors oversees sustainability issues, with Chairman and Managing Director Venkateswarlu Jasti responsible for BRSR matters. The company aligns its policies with National Guidelines on Responsible Business Conduct (NGRBC) and holds NABL accreditation for its laboratory. Material risks identified include clinical trial failures and drug safety monitoring issues, both carrying negative financial implications. The company mitigates these through proactive risk assessment, qualified investigative teams, and independent Data Safety Monitoring Boards during Phase 2 and Phase 3 trials.

No fines, penalties, or disciplinary actions for bribery or corruption were recorded. The company maintains an anti-corruption policy and a whistle-blower mechanism. Zero complaints related to sexual harassment, discrimination, or human rights violations were filed in FY26.